Tags

Type your tag names separated by a space and hit enter

Mid-season influenza vaccine effectiveness 2011-2012: a Department of Defense Global, Laboratory-based, Influenza Surveillance System case-control study estimate.
Vaccine 2013; 31(13):1651-5V

Abstract

Mid-season influenza vaccine effectiveness (VE) was estimated using data from surveillance conducted by the Department of Defense Global, Laboratory-based, Influenza Surveillance Program at the United States Air Force School of Aerospace Medicine. Respiratory specimens from geographically diverse military members and dependents who sought medical care 2 October 2011-3 March 2012 were analyzed by viral culture and real-time reverse transcriptase-polymerase chain reaction; influenza viruses were typed and sequenced. Controls were influenza test-negative. Overall, vaccine type and subtype-specific VE were estimated using logistic regression. Adjusted VE (95% confidence interval) was: overall 77 (57-87)%; live attenuated vaccine (LAIV) 74 (48-87)%; trivalent inactivated vaccine (TIV) 75 (48-88)%. H3 component-specific VE was: overall 77 (52-89)%; LAIV 78 (47-91)%; TIV 74 (38-89)%; data were insufficient for separate H1 and B estimates. Both vaccine types showed moderate to high VE, indicating significant protection against circulating influenza strains.

Authors+Show Affiliations

United States Air Force School of Aerospace Medicine, 2510 5th Street, Wright-Patterson Air Force Base, OH 45433, United States. Victor.MacIntosh@us.af.milNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, U.S. Gov't, Non-P.H.S.

Language

eng

PubMed ID

23395733

Citation

MacIntosh, Victor H., et al. "Mid-season Influenza Vaccine Effectiveness 2011-2012: a Department of Defense Global, Laboratory-based, Influenza Surveillance System Case-control Study Estimate." Vaccine, vol. 31, no. 13, 2013, pp. 1651-5.
MacIntosh VH, Tastad KJ, Eick-Cost AA. Mid-season influenza vaccine effectiveness 2011-2012: a Department of Defense Global, Laboratory-based, Influenza Surveillance System case-control study estimate. Vaccine. 2013;31(13):1651-5.
MacIntosh, V. H., Tastad, K. J., & Eick-Cost, A. A. (2013). Mid-season influenza vaccine effectiveness 2011-2012: a Department of Defense Global, Laboratory-based, Influenza Surveillance System case-control study estimate. Vaccine, 31(13), pp. 1651-5. doi:10.1016/j.vaccine.2013.01.022.
MacIntosh VH, Tastad KJ, Eick-Cost AA. Mid-season Influenza Vaccine Effectiveness 2011-2012: a Department of Defense Global, Laboratory-based, Influenza Surveillance System Case-control Study Estimate. Vaccine. 2013 Mar 25;31(13):1651-5. PubMed PMID: 23395733.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Mid-season influenza vaccine effectiveness 2011-2012: a Department of Defense Global, Laboratory-based, Influenza Surveillance System case-control study estimate. AU - MacIntosh,Victor H, AU - Tastad,Katie J, AU - Eick-Cost,Angelia A, Y1 - 2013/02/06/ PY - 2012/04/20/received PY - 2013/01/06/revised PY - 2013/01/14/accepted PY - 2013/2/12/entrez PY - 2013/2/12/pubmed PY - 2013/8/24/medline SP - 1651 EP - 5 JF - Vaccine JO - Vaccine VL - 31 IS - 13 N2 - Mid-season influenza vaccine effectiveness (VE) was estimated using data from surveillance conducted by the Department of Defense Global, Laboratory-based, Influenza Surveillance Program at the United States Air Force School of Aerospace Medicine. Respiratory specimens from geographically diverse military members and dependents who sought medical care 2 October 2011-3 March 2012 were analyzed by viral culture and real-time reverse transcriptase-polymerase chain reaction; influenza viruses were typed and sequenced. Controls were influenza test-negative. Overall, vaccine type and subtype-specific VE were estimated using logistic regression. Adjusted VE (95% confidence interval) was: overall 77 (57-87)%; live attenuated vaccine (LAIV) 74 (48-87)%; trivalent inactivated vaccine (TIV) 75 (48-88)%. H3 component-specific VE was: overall 77 (52-89)%; LAIV 78 (47-91)%; TIV 74 (38-89)%; data were insufficient for separate H1 and B estimates. Both vaccine types showed moderate to high VE, indicating significant protection against circulating influenza strains. SN - 1873-2518 UR - https://www.unboundmedicine.com/medline/citation/23395733/Mid_season_influenza_vaccine_effectiveness_2011_2012:_a_Department_of_Defense_Global_Laboratory_based_Influenza_Surveillance_System_case_control_study_estimate_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(13)00079-0 DB - PRIME DP - Unbound Medicine ER -